glp 1 gip dual agonist mechanism of action Mechanisms and effects of GLP‐1 receptor agonists and TIRZEPATIDE Mechanism of action of

GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally

Hsia DS, Grove O, Cefalu WT

Similar findings were reported in a 2025 real-world analysis of over ten thousand patients: tirzepatide lowered HbA1c by 1.3% and body weight by 10.2 kg, compared with 0.9% and 6.1 kg with semaglutide after 12 months [7]

The STEP and SUSTAIN trial data provide robust evidence of systemic anti-inflammatory effects

many manufacturers also have savings programs, so check your eligibility before paying full price

Characterizing a new tool to manipulate area postrema GLP1R+ neurons across species